tp21 is your managing partner for your interdisciplinary research project, your multi-center clinical trial or your technology transfer plans.
RexPo23
The 2nd international conference on
SYSTEMS MEDICINE, AI & DRUG REPURPOSING
October 25-26 2023 - Stockholm, SwedenRegister NOW
tp21 is managing partner in TEF-Health
Coordinated by Prof. Dr. Petra Ritter - CHARITE - Universitätsmedizin Berlin (DE), project management by tp21.
37 Partners - TEF-Health project awarded € 60 million for Testing and Experimentation Facility for Health AI and Robotics (EU funding and national fundings)
From the lab to the market
TEF-Health will develop a reference Testing and Experimentation Facility (TEF) with a focus on full integration, testing and validation of advanced AI-based technologies and robotics technologies for health and care.
It aims to accelerate the testing and certifications, to speed up the development and the market access of trustworthy AI solutions in Europe, for both private and public sector use. TEF-Health intends to increase the effectiveness, resilience and sustainability of European health and care systems, and reduce healthcare delivery inequalities in Europe, while ensuring compliance with relevant legal, ethical, quality and interoperability requirements.
more soon on the project website
more on the CORDIS website
EU project IntReALL 2020 started
Coordinated by PD Dr. med. Arend von Stackelberg, Pädiatrie m. S. Onkologie/Hämatologie - CHARITE - Universitätsmedizin Berlin (DE), project management by tp21.
Duration: 5 years - Project start: 01 May 2023
Vision...
Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct
randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic
chemotherapy with better tolerated and more efficacious immunotherapeutic drugs. In standard risk (SR) patients, the CD22 directed
antibody-drug conjugate inotuzumab ozogamicin (InO) will be randomly compared with standard of care (SOC) ALL-R3 induction. All
patients will receive one SOC consolidation- and one Blina course, compared to historical controls. SR patients with MRD good response
will receive 2 additional Blina courses replacing chemotherapy randomly compared with SOC. Patients with high-risk relapse will
receive induction investigating InO versus ALL-R3 in an industry-sponsored trial, followed by IntReALL consolidation and allogeneic
HSCT. Patients with isolated extramedullary (IEM) relapse are treated based on ALL-REZ BFM 2002 backbone. IntReALL 2020 will
establish a federated relapsed/refractory leukaemia board generating personalized recommendations based on clinical, molecular-genetic
and drug response profiling data. Patients with very-high risk disease will receive experimental/personalized therapies, including a trial
investigating CD19-directed chimeric receptor antigen (CAR) T-cells produced in academic institutions. Other CAR T-cells trials as well
as an induction trial for T-ALL relapse will be developed. Documentation and monitoring of the trials and the individualized treatment
will be realized using the MARVIN database. Comprehensive statistical and data management activities will warrant the accuracy and
interpretability of the data. IntReALL 2020 involves representatives from participating pharmaceutical companies and EMA as well as
patient/parent advocates to discuss strategies for developing new drugs within academic trials warranting a benefit for all patients on the
results. “This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
more soon